Back to Search
Start Over
Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer
- Source :
- Legal Monitor Worldwide. December 16, 2020
- Publication Year :
- 2020
-
Abstract
- Verastem Oncology, Inc. (Nasdaq:VSTM) , a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the initiation of a Phase 2 registration-directed clinical trial of VS-6766, [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Legal Monitor Worldwide
- Publication Type :
- News
- Accession number :
- edsgcl.645194608